ONIVYDE (pegylated liposomal irinotecan hydrochloride trihydrate, nal-IRI) in combination with 5-fluorouracil and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas in patients who have progressed following gemcitabine based therapy received a marketing authorization from The European Commission. The agent is sponsored by Shire. Wth this approval, Shire is authorized to market Onivyde in...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
